Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum

被引：13

作者：

Selva-Nayagam, Priya ^{[1
,2
]}

Fischer, Gayle ^{[3
,4
]}

Hamann, Ian ^{[5
,6
]}

Sobel, Jack ^{[7
]}

James, Craig

机构：

[1] Queen Elizabeth Hosp, Dept Dermatol, Adelaide, SA, Australia

[2] Royal Adelaide Hosp, Dept Gynecol, Adelaide, SA 5000, Australia

[3] Royal N Shore Hosp, Dept Dermatol, Sydney, NSW, Australia

[4] Univ Sydney, Sydney, NSW 2006, Australia

[5] Mid North Coast Dermatol, Port Macquarie, Australia

[6] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia

[7] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI USA

来源：

CURRENT INFECTIOUS DISEASE REPORTS | 2015年 / 17卷 / 05期

关键词：

Vulvovaginal pyoderma gangrenosum; Rituximab; Vulvovaginal ulceration; Intravenous immunoglobulin; Non Hodgkin's lymphoma; Neutrophilic dermatosis; Pyoderma gangrenosum; Rituximab complications; Vulvovaginal discharge; VULVAR PYODERMA-GANGRENOSUM; GENITAL ULCERS; MANAGEMENT; EXPRESSION; THERAPY;

D O I：

10.1007/s11908-015-0478-5

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Pyoderma gangrenosum (PG) is a rare cause of purulent vulvovaginal ulceration. Six recent cases of vulvovaginal pyoderma gangrenosum associated with rituximab are described. All cases were seen in the setting of rituximab used for the treatment of B cell non Hodgkin's lymphoma (NHL). Age range was 50-74; symptoms were present for 2-24 months and severe pain, heavy discharge and large, deep purulent ulcers extending into the vagina were seen. This article reviews previous reports of vulvovaginal pyoderma gangrenosum, discusses important differential diagnoses in this setting, and provides evidence supporting rituximab as the cause of pyoderma gangrenosum in this cohort.

引用

页码：1 / 6

页数：6

共 29 条

[1] Therapeutic Antibodies Against Cancer [J].